Apart from the cutaneous pathological processes inherent to T2DM and local reactions, contact dermatitis, and lipohypertrophy at insulin injection sites, there are a variety of CADRs in T2DM patients, and our work focused on CADRs linked to SGLT2 inhibitors, the latest and highly promising oral hypoglycemic agents with relatively fewer side effects and broader areas of benefits in the range of cardiovascular and renal systems. Here, INS is linked to type 2 diabetes mellitus.